Annual EBIT
$11.75 M
+$23.61 M+198.97%
December 31, 2023
Summary
- As of February 8, 2025, PLX annual earnings before interest & taxes is $11.75 million, with the most recent change of +$23.61 million (+198.97%) on December 31, 2023.
- During the last 3 years, PLX annual EBIT has risen by +$8.60 million (+273.13%).
- PLX annual EBIT is now at all-time high.
Performance
PLX EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
$4.14 M
+$6.05 M+317.43%
September 30, 2024
Summary
- As of February 8, 2025, PLX quarterly earnings before interest & taxes is $4.14 million, with the most recent change of +$6.05 million (+317.43%) on September 30, 2024.
- Over the past year, PLX quarterly EBIT has increased by +$5.40 million (+428.99%).
- PLX quarterly EBIT is now -80.23% below its all-time high of $20.95 million, reached on June 30, 2023.
Performance
PLX Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$7.76 M
+$5.40 M+41.04%
September 30, 2024
Summary
- As of February 8, 2025, PLX TTM earnings before interest & taxes is -$7.76 million, with the most recent change of +$5.40 million (+41.04%) on September 30, 2024.
- Over the past year, PLX TTM EBIT has dropped by -$22.60 million (-152.26%).
- PLX TTM EBIT is now -152.26% below its all-time high of $14.85 million, reached on September 30, 2023.
Performance
PLX TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
PLX EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +199.0% | +429.0% | -152.3% |
| 3 y3 years | +273.1% | +429.0% | -152.3% |
| 5 y5 years | +162.6% | +429.0% | -152.3% |
PLX EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +158.6% | -80.2% | +171.9% | -152.3% | +61.0% |
| 5 y | 5-year | at high | +158.6% | -80.2% | +145.8% | -152.3% | +61.0% |
| alltime | all time | at high | +115.9% | -80.2% | +107.3% | -152.3% | +89.6% |
Protalix BioTherapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $4.14 M(-317.4%) | -$7.76 M(-41.0%) |
| Jun 2024 | - | -$1.91 M(-56.1%) | -$13.16 M(-235.7%) |
| Mar 2024 | - | -$4.34 M(-23.2%) | $9.70 M(-17.5%) |
| Dec 2023 | $11.75 M(-199.0%) | -$5.65 M(+348.9%) | $11.75 M(-20.8%) |
| Sep 2023 | - | -$1.26 M(-106.0%) | $14.85 M(+12.7%) |
| Jun 2023 | - | $20.95 M(-1016.1%) | $13.18 M(-205.5%) |
| Mar 2023 | - | -$2.29 M(-10.7%) | -$12.49 M(+5.2%) |
| Dec 2022 | -$11.87 M(-40.8%) | -$2.56 M(-12.6%) | -$11.87 M(-21.2%) |
| Sep 2022 | - | -$2.93 M(-37.8%) | -$15.07 M(+8.2%) |
| Jun 2022 | - | -$4.71 M(+182.4%) | -$13.93 M(-23.7%) |
| Mar 2022 | - | -$1.67 M(-71.0%) | -$18.25 M(-8.3%) |
| Dec 2021 | -$20.06 M(-737.3%) | -$5.76 M(+221.9%) | -$19.91 M(+77.3%) |
| Sep 2021 | - | -$1.79 M(-80.2%) | -$11.23 M(-5.7%) |
| Jun 2021 | - | -$9.04 M(+172.3%) | -$11.90 M(+134.9%) |
| Mar 2021 | - | -$3.32 M(-213.7%) | -$5.07 M(-261.0%) |
| Dec 2020 | $3.15 M(-130.5%) | $2.92 M(-218.4%) | $3.15 M(+20.6%) |
| Sep 2020 | - | -$2.46 M(+11.9%) | $2.61 M(-26.8%) |
| Jun 2020 | - | -$2.20 M(-145.0%) | $3.56 M(-5191.4%) |
| Mar 2020 | - | $4.90 M(+105.7%) | -$70.00 K(-99.3%) |
| Dec 2019 | -$10.31 M(-45.1%) | $2.38 M(-257.6%) | -$10.31 M(-36.6%) |
| Sep 2019 | - | -$1.51 M(-74.1%) | -$16.26 M(-11.0%) |
| Jun 2019 | - | -$5.84 M(+9.2%) | -$18.26 M(-4.4%) |
| Mar 2019 | - | -$5.34 M(+49.6%) | -$19.10 M(+1.7%) |
| Dec 2018 | -$18.77 M(-74.5%) | -$3.57 M(+1.8%) | -$18.77 M(-32.0%) |
| Sep 2018 | - | -$3.51 M(-47.4%) | -$27.59 M(-13.3%) |
| Jun 2018 | - | -$6.67 M(+32.9%) | -$31.83 M(+46.9%) |
| Mar 2018 | - | -$5.02 M(-59.5%) | -$21.67 M(-70.6%) |
| Dec 2017 | -$73.72 M(+195.0%) | -$12.39 M(+59.7%) | -$73.71 M(+18.0%) |
| Sep 2017 | - | -$7.76 M(-321.9%) | -$62.47 M(+2.3%) |
| Jun 2017 | - | $3.50 M(-106.1%) | -$61.09 M(-17.9%) |
| Mar 2017 | - | -$57.06 M(+4874.8%) | -$74.42 M(+197.9%) |
| Dec 2016 | -$24.98 M(+6.1%) | -$1.15 M(-82.0%) | -$24.98 M(-20.6%) |
| Sep 2016 | - | -$6.38 M(-35.1%) | -$31.48 M(+4.6%) |
| Jun 2016 | - | -$9.84 M(+29.0%) | -$30.08 M(+16.7%) |
| Mar 2016 | - | -$7.62 M(-0.2%) | -$25.79 M(+9.6%) |
| Dec 2015 | -$23.55 M(-17.0%) | -$7.64 M(+53.3%) | -$23.52 M(-10.4%) |
| Sep 2015 | - | -$4.99 M(-10.0%) | -$26.26 M(-4.3%) |
| Jun 2015 | - | -$5.54 M(+3.5%) | -$27.43 M(+1.1%) |
| Mar 2015 | - | -$5.36 M(-48.4%) | -$27.14 M(-3.8%) |
| Dec 2014 | -$28.36 M(-15.8%) | -$10.38 M(+68.5%) | -$28.21 M(-18.8%) |
| Sep 2014 | - | -$6.16 M(+17.4%) | -$34.75 M(+1.6%) |
| Jun 2014 | - | -$5.25 M(-18.4%) | -$34.21 M(-4.4%) |
| Mar 2014 | - | -$6.43 M(-62.0%) | -$35.79 M(+6.3%) |
| Dec 2013 | -$33.67 M(+190.7%) | -$16.92 M(+201.3%) | -$33.67 M(+27.9%) |
| Sep 2013 | - | -$5.62 M(-17.8%) | -$26.33 M(+0.2%) |
| Jun 2013 | - | -$6.83 M(+58.5%) | -$26.27 M(+167.4%) |
| Mar 2013 | - | -$4.31 M(-55.0%) | -$9.83 M(-15.2%) |
| Dec 2012 | -$11.58 M(-68.3%) | -$9.58 M(+72.3%) | -$11.58 M(+6.6%) |
| Sep 2012 | - | -$5.56 M(-157.8%) | -$10.86 M(-22.8%) |
| Jun 2012 | - | $9.62 M(-258.6%) | -$14.07 M(-56.3%) |
| Mar 2012 | - | -$6.07 M(-31.5%) | -$32.18 M(+3.3%) |
| Dec 2011 | -$36.53 M | -$8.86 M(+1.0%) | -$31.15 M(+0.0%) |
| Sep 2011 | - | -$8.77 M(+3.3%) | -$31.14 M(+23.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2011 | - | -$8.49 M(+68.4%) | -$25.22 M(-4.3%) |
| Mar 2011 | - | -$5.04 M(-43.1%) | -$26.36 M(-10.5%) |
| Dec 2010 | -$29.97 M(-6.3%) | -$8.85 M(+210.7%) | -$29.44 M(-17.3%) |
| Sep 2010 | - | -$2.85 M(-70.4%) | -$35.60 M(-8.2%) |
| Jun 2010 | - | -$9.62 M(+18.5%) | -$38.80 M(+10.7%) |
| Mar 2010 | - | -$8.12 M(-45.9%) | -$35.05 M(+9.6%) |
| Dec 2009 | -$31.97 M(+32.3%) | -$15.02 M(+148.3%) | -$31.97 M(+37.5%) |
| Sep 2009 | - | -$6.05 M(+2.9%) | -$23.25 M(-2.8%) |
| Jun 2009 | - | -$5.87 M(+16.6%) | -$23.92 M(+4.2%) |
| Mar 2009 | - | -$5.04 M(-20.0%) | -$22.94 M(-5.1%) |
| Dec 2008 | -$24.17 M(-29.3%) | -$6.29 M(-6.3%) | -$24.17 M(-27.8%) |
| Sep 2008 | - | -$6.72 M(+37.2%) | -$33.50 M(+0.9%) |
| Jun 2008 | - | -$4.90 M(-21.8%) | -$33.21 M(-11.8%) |
| Mar 2008 | - | -$6.26 M(-59.9%) | -$37.65 M(+7.1%) |
| Dec 2007 | -$34.16 M(+249.6%) | -$15.62 M(+142.8%) | -$35.16 M(+51.0%) |
| Sep 2007 | - | -$6.43 M(-31.1%) | -$23.28 M(+20.1%) |
| Jun 2007 | - | -$9.34 M(+146.9%) | -$19.39 M(+43.1%) |
| Mar 2007 | - | -$3.78 M(+1.2%) | -$13.55 M(+18.8%) |
| Dec 2006 | -$9.77 M(+68.8%) | -$3.73 M(+47.2%) | -$11.41 M(-14.8%) |
| Sep 2006 | - | -$2.54 M(-27.5%) | -$13.39 M(+23.0%) |
| Jun 2006 | - | -$3.50 M(+113.7%) | -$10.89 M(+46.9%) |
| Mar 2006 | - | -$1.64 M(-71.4%) | -$7.42 M(+28.1%) |
| Dec 2005 | -$5.79 M(+139.5%) | -$5.72 M(>+9900.0%) | -$5.79 M(+146.3%) |
| Sep 2005 | - | -$35.90 K(+76.0%) | -$2.35 M(-0.3%) |
| Jun 2005 | - | -$20.40 K(+87.2%) | -$2.36 M(-1.6%) |
| Mar 2005 | - | -$10.90 K(-99.5%) | -$2.40 M(-0.8%) |
| Dec 2004 | -$2.42 M(+1539.8%) | -$2.28 M(+5101.6%) | -$2.42 M(+1225.1%) |
| Sep 2004 | - | -$43.90 K(-26.7%) | -$182.40 K(+6.4%) |
| Jun 2004 | - | -$59.90 K(+101.7%) | -$171.50 K(+20.3%) |
| Mar 2004 | - | -$29.70 K(-39.3%) | -$142.60 K(-3.3%) |
| Dec 2003 | -$147.40 K(-11.1%) | -$48.90 K(+48.2%) | -$147.50 K(-2.4%) |
| Sep 2003 | - | -$33.00 K(+6.5%) | -$151.10 K(-1.8%) |
| Jun 2003 | - | -$31.00 K(-10.4%) | -$153.90 K(-3.7%) |
| Mar 2003 | - | -$34.60 K(-34.1%) | -$159.80 K(-3.6%) |
| Dec 2002 | -$165.80 K(-57.0%) | -$52.50 K(+46.6%) | -$165.80 K(-38.5%) |
| Sep 2002 | - | -$35.80 K(-3.0%) | -$269.50 K(-7.8%) |
| Jun 2002 | - | -$36.90 K(-9.1%) | -$292.40 K(-8.8%) |
| Mar 2002 | - | -$40.60 K(-74.0%) | -$320.50 K(-16.9%) |
| Dec 2001 | -$385.80 K(+1.0%) | -$156.20 K(+166.1%) | -$385.70 K(-14.3%) |
| Sep 2001 | - | -$58.70 K(-9.7%) | -$449.80 K(+10.6%) |
| Jun 2001 | - | -$65.00 K(-38.6%) | -$406.70 K(-3.1%) |
| Mar 2001 | - | -$105.80 K(-52.0%) | -$419.50 K(+9.8%) |
| Dec 2000 | -$381.90 K(-53.2%) | -$220.30 K(+1312.2%) | -$381.90 K(+26.2%) |
| Sep 2000 | - | -$15.60 K(-79.9%) | -$302.70 K(-57.4%) |
| Jun 2000 | - | -$77.80 K(+14.1%) | -$710.90 K(-12.5%) |
| Mar 2000 | - | -$68.20 K(-51.7%) | -$812.00 K(-0.5%) |
| Dec 1999 | -$816.20 K(-30.5%) | -$141.10 K(-66.7%) | -$816.20 K(+20.9%) |
| Sep 1999 | - | -$423.80 K(+136.9%) | -$675.10 K(+168.6%) |
| Jun 1999 | - | -$178.90 K(+147.1%) | -$251.30 K(+247.1%) |
| Mar 1999 | - | -$72.40 K | -$72.40 K |
| Dec 1998 | -$1.17 M(+614.2%) | - | - |
| Dec 1997 | -$164.40 K(+272.8%) | - | - |
| Dec 1996 | -$44.10 K | - | - |
FAQ
- What is Protalix BioTherapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Protalix BioTherapeutics?
- What is Protalix BioTherapeutics annual EBIT year-on-year change?
- What is Protalix BioTherapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Protalix BioTherapeutics?
- What is Protalix BioTherapeutics quarterly EBIT year-on-year change?
- What is Protalix BioTherapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Protalix BioTherapeutics?
- What is Protalix BioTherapeutics TTM EBIT year-on-year change?
What is Protalix BioTherapeutics annual earnings before interest & taxes?
The current annual EBIT of PLX is $11.75 M
What is the all time high annual EBIT for Protalix BioTherapeutics?
Protalix BioTherapeutics all-time high annual earnings before interest & taxes is $11.75 M
What is Protalix BioTherapeutics annual EBIT year-on-year change?
Over the past year, PLX annual earnings before interest & taxes has changed by +$23.61 M (+198.97%)
What is Protalix BioTherapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of PLX is $4.14 M
What is the all time high quarterly EBIT for Protalix BioTherapeutics?
Protalix BioTherapeutics all-time high quarterly earnings before interest & taxes is $20.95 M
What is Protalix BioTherapeutics quarterly EBIT year-on-year change?
Over the past year, PLX quarterly earnings before interest & taxes has changed by +$5.40 M (+428.99%)
What is Protalix BioTherapeutics TTM earnings before interest & taxes?
The current TTM EBIT of PLX is -$7.76 M
What is the all time high TTM EBIT for Protalix BioTherapeutics?
Protalix BioTherapeutics all-time high TTM earnings before interest & taxes is $14.85 M
What is Protalix BioTherapeutics TTM EBIT year-on-year change?
Over the past year, PLX TTM earnings before interest & taxes has changed by -$22.60 M (-152.26%)